David D. Helsel's most recent trade in Angiodynamic Inc was a trade of 365 Common Stock done at an average price of $8.6 . Disclosure was reported to the exchange on July 20, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 365 | 28,289 (0%) | 0% | 8.6 | 3,157 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 332 | 28,654 (0%) | 0% | 8.7 | 2,902 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 15,081 | 0 | - | - | Performance Right | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 4,371 | 32,660 (0%) | 0% | 0 | Common Stock | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 19 Jul 2023 | 1,575 | 31,085 (0%) | 0% | 8.9 | 14,049 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 14 Jul 2023 | 679 | 18,510 (0%) | 0% | 9.6 | 6,539 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.56 per share. | 14 Jul 2023 | 313 | 18,197 (0%) | 0% | 9.6 | 2,992 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 12.95 per share. | 31 Jan 2023 | 4,633 | 19,189 (0%) | 0% | 12.9 | 59,997 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 22.44 per share. | 29 Jul 2022 | 5,000 | 23,822 (0%) | 0% | 22.4 | 112,200 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 8,646 | 8,646 | - | - | Non-Qualified Stock Option (right to buy) | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,381 | 7,381 | - | - | Performance Right | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,691 | 28,822 (0%) | 0% | 0 | Common Stock | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 6,945 | 0 | - | - | Performance Right | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 3,480 | 26,354 (0%) | 0% | 0 | Common Stock | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.54 per share. | 07 Jul 2022 | 1,223 | 25,131 (0%) | 0% | 20.5 | 25,120 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 22.44 per share. | 28 Apr 2022 | 3,513 | 22,874 (0%) | 0% | 22.4 | 78,832 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 27.97 per share. | 20 Oct 2021 | 3,494 | 26,387 (0%) | 0% | 28.0 | 97,727 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 11,406 | 33,228 (0%) | 0% | 0 | Common Stock | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 9,834 | 0 | - | - | Performance Right | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.29 per share. | 12 Aug 2021 | 3,347 | 29,881 (0%) | 0% | 27.3 | 91,340 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 11,026 | 11,026 | - | - | Non-Qualified Stock Option (right to buy) | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 23.93 per share. | 14 Apr 2021 | 3,500 | 19,115 (0%) | 0% | 23.9 | 83,755 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.29 per share. | 18 Dec 2020 | 733 | 22,615 (0%) | 0% | 14.3 | 10,475 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.46 per share. | 17 Jul 2020 | 254 | 23,708 (0%) | 0% | 9.5 | 2,403 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 207 | 23,501 (0%) | 0% | 9.2 | 1,906 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 155 | 23,348 (0%) | 0% | 9.2 | 1,428 | Common Stock |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 22,196 | 22,196 | - | - | Non-Qualified Stock Option (right to buy) | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,081 | 15,081 | - | - | Performance Right | |
| Angiodynamic Inc | David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 7,540 | 23,962 (0%) | 0% | 0 | Common Stock |